ArticleJournal of pain research2025
Efficacy of Dexamethasone as an Adjuvant for Scalp Nerve Blocks to Prolong Analgesia: A Prospective, Double-Blind, Randomized Controlled Study.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Scalp nerve blocks (SNB) may significantly reduce post-craniotomy pain (PCP) but only for a short period of time. Dexamethasone, as an adjuvant to local anesthetics, was reported to prolong the analgesia duration of never block; however, the addition of dexamethasone to SNB is rare. We therefore tested the hypothesis that dexamethasone as an adjuvant to bupivacaine in SNB is positive after craniotomy. Methods: Patients elective for craniotomy were randomly assigned to receive SNB with bupivacaine alone compared with dexamethasone and bupivacaine. The primary outcome was the duration of analgesia. The secondary outcomes include the cumulative amount of sufentanil consumption, the numeric rating scale (NRS), patient satisfaction score (PSS), the complications during the postoperative period, and SNB's relevant adverse events. Results: There were 156 subjects included and 78 patients in each group (control and DEX group). The analgesia duration was significantly prolonged in the DEX group compared with the control group (660min (390,1005) vs 420min (314,504)) (p<0.001). The postoperative sufentanil consumption was lower in the DEX group compared with the control group at 12h (P<0.001), 24h (P=0.014), and 48h (P=0.049). The NRS scores were significantly lower in the DEX group compared with the control group at 8h (P<0.001) and 12h (P=0.007) after craniotomy. From 4h to 16h postoperative, the PSS in the control group was lower than the DEX group (P < 0.05). Conclusion: Perineural dexamethasone as an adjuvant to bupivacaine without background glucocorticoid has the potential to improve the postoperative analgesic effect and patients' satisfaction without serious complications after craniotomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.